

Chapter 1

Orientation to the research

1.1	INTRODUCTION	1
1.2	BACKGROUND OF THE RESEARCH	2
1.2.1	Factors which influence the tuberculosis rates	6
1.2.2	Measures used to combat tuberculosis in the past	7
1.2.3	Implementation of the directly observed treatment short course strategy	8
1.3	RATIONALE OF THE RESEARCH	8
1.4	SIGNIFICANCE OF THE RESEARCH	9
1.5	AIM OF THE RESEARCH	10
1.5.1	Research objectives	10
1.6	STATEMENT OF THE PROBLEM	11
1.7	OPERATIONAL DEFINITIONS	11
1.8	RESEARCH METHODOLOGY	13
1.8.1	Research approach: quantitative research	14
1.8.2	Research design	14
1.8.3	Research problem	14
1.8.4	Research sample and sampling method	1
1.8.5	Data collection	15
1.9	RELIABILITY AND VALIDITY OF THE STUDY	15
1.10	AN OVERVIEW OF THE ETHICAL CONSIDERATIONS OF THIS RESEARCH	16
1.11	LIMITATIONS OF THIS RESEARCH	17
1.12	LAYOUT OF THE RESEARCH	17
1.13	SUMMARY	18

Chapter 2

Literature review

2.1	INTRODUCTION	19
2.2	TUBERCULOSIS AS A HEALTH PROBLEM	19

Table of contents		Page
2.3	IMPACT OF HIV/AIDS ON THE INCIDENCE OF TUBERCULOSIS IN SUB-SAHARA AFRICA	21
2.4	EXTENT OF THE TUBERCULOSIS HEALTH PROBLEM	22
2.5	TREATMENT OF TUBERCULOSIS (FOR ADULTS IN 1997)	25
2.6	REASONS FOR FAILURE OF TUBERCULOSIS TREATMENT IN THE PAST	27
2.7	THE DIRECTLY OBSERVED TREATMENT SHORT COURSE	28
2.7.1	Advantages of the directly observed treatment short course strategy	28
2.7.1.1	Global recognition	28
2.7.1.2	Reduces treatment interruption rate	29
2.7.1.3	Easy to implement	29
2.7.1.4	Enhance patient support	29
2.7.1.5	Affordable	30
2.7.1.6	Increases knowledge	31
2.7.1.7	Acceptability by the TB patient	32
2.8	SUMMARY	32

Chapter 3

Research methodology

3.1	INTRODUCTION	33
3.2	DELIMITATION OF THE RESEARCH	33
3.3	GEOGRAPHICAL AREA	34
3.4	RESEARCH DESIGN	35
3.4.1	Quantitative research	35
3.4.1.1	Characteristics of quantitative research approach	35
3.4.2	Cross-sectional research	36
3.5	RESEARCH POPULATION	36
3.6	SAMPLING	37
3.6.1	Sampling method	38
3.6.2	Sample size	39
3.6.2	Advantages of the purposive sampling method	40
3.6.3	Disadvantages of the purposive sampling method	40
3.6.4	Criteria set for a respondent to be included in the sample	41
3.7	DATA COLLECTION METHOD	41

Table of contents Page

3.7.1	Interviews	41
3.7.2	Research instrument	42
3.7.3	Interview schedule	43
3.8	ANALYSIS OF THE DATA	45
3.9	RELIABILITY AND VALIDITY OF THE RESEARCH	45
3.10	ETHICAL CONSIDERATION OF THIS RESEARCH	47
3.11	SUMMARY	51

Chapter 4

Data analysis and interpretation

4.1	INTRODUCTION	52
4.2	SAMPLING	53
4.3	DISCUSSION AND INTERPRETATION OF DATA OBTAINED FROM THE INTERVIEW SCHEDULES	53
4.3.1	Biographical information	53
4.3.2	Knowledge of tuberculosis	56
4.3.3	Previous experience as tuberculosis patient	79
4.4	INTERPRETATION OF FINDINGS	122
4.5	CONCLUSION	125

Chapter 5

Summary, findings, conclusions and recommendations

5.1	INTRODUCTION	126
5.2	SUMMARY OF THE RESEARCH	126
5.3	CONCLUSIONS	134
5.4	RECOMMENDATIONS FOR THE IMPROVEMENT OF THE DIRECTLY OBSERVED TREATMENT SHORT COURSE STRATEGY	134
5.5	RECOMMENDATIONS FOR FURTHER RESEARCH	135
5.6	LIMITATIONS	136
5.7	SUMMARY OF THIS CHAPTER	136

Table of contents**Page**

BIBLIOGRAPHY	137
ANNEXURES	

List of table**Page**

Table 2.1	Incidence rate per 100 000 in South Africa	20
Table 2.2	Projected impact of HIV+ cases on tuberculosis	22
Table 2.3	Current tuberculosis treatment	26
Table 4.1	Age categories of respondents	53
Table 4.2	Respondents type of work	55
Table 4.3	Patients' knowledge of the acronym tuberculosis	57
Table 4.4	Tuberculosis as an infectious disease	57
Table 4.5	Fatality of tuberculosis	58
Table 4.6	Causes of tuberculosis	59
Table 4.7	Respondents opinion on how to recognise a person with tuberculosis	59
Table 4.8	Most serious of listed conditions	60
Table 4.9	Respondents' understanding on how multi-drug resistant tuberculosis develops	71
Table 4.10	Reasons for interrupting treatment	71
Table 4.11	Whether HIV positive people can be successfully treated for tuberculosis	72
Table 4.12	Respondents' opinion on how tuberculosis is prevented	74
Table 4.13	Reasons the respondents were not cured	80
Table 4.14	Patients' frequency in consulting health professionals	86
Table 4.15	Patients' frequency in consulting health professionals	88
Table 4.16	Reasons why respondents might default treatment before completion in current infection	89
Table 4.17	Medication taken by patients	92
Table 4.18	Side effect the patients can expect when taking tuberculosis drugs	95
Table 4.19	Patients' regularity of taking their medicine	96
Table 4.20	Support from other people	101
Table 4.21	Respondent's opinion on the knowledge of the treatment supporter about various aspects of tuberculosis	111
Table 4.22	When have you heard about the directly observed treatment short course strategy for the first time?	115
Table 4.23	Sources from where the patients heard about the directly observed treatment short course strategy	116

Table 4.24	Patients' knowledge about what the directly observed treatment short course strategy is about ...	117
Table 4.25	Respondents' reasons why the directly observed treatment short course strategy should continue	118

List of figures

Page

Figure 4.1	Gender of respondents	54
Figure 4.2	Cultural groups of respondents	54
Figure 4.3	Marital status of respondents	56
Figure 4.4	Coughing as one of the first important signs and symptoms of tuberculosis	63
Figure 4.5	Weight loss as one of the first important signs and symptoms of tuberculosis	64
Figure 4.6	Night sweats as one of the first important signs and symptoms of tuberculosis	65
Figure 4.7	Opinion of the respondents on the importance of completing tuberculosis treatment	69
Figure 4.8	Knowledge of respondents about what the term <i>multi-drug resistant</i> tuberculosis means	70
Figure 4.9	Respondents' reasons why tuberculosis patients generally default treatment	75
Figure 4.10	People from whom respondents obtained knowledge of tuberculosis	78
Figure 4.11	Support received by the patients from family	82
Figure 4.12	Support received by the patients from friends	83
Figure 4.13	Support received by the patients from employer	83
Figure 4.14	Support received by the patients from community	84
Figure 4.15	Support received by the patients from nurses	85
Figure 4.16	Support received by the patients from medical practitioners	86
Figure 4.17	Duration of current infection	87
Figure 4.18	Explanation of the side effects of drugs to the patient	94
Figure 4.19	Patients' opinion on a possibility of stigma attached to tuberculosis	97
Figure 4.20	Knowledge of the treatment supporter about signs and symptoms of tuberculosis	107
Figure 4.21	Importance of taking treatment regularly	108

List of abbreviations

AIDS	Acquired immune-deficiency syndrome
HIV	Human immuno-deficiency virus
DOTS	Directly observed treatment short course
MDR	Multi-drug resistance
SA	South Africa
TB	Tuberculosis

List of annexures

Annexure A	Questionnaire
Annexure B	Permission requested and received to conduct research
Annexure C	Informed consent
Annexure D	Map of research
Annexure E	Example of patient clinic records